IDT has received inquiries from researchers from around the world who are interested in rapidly obtaining assays and developing vaccines targeting the novel coronavirus (2019-nCoV/SARS-CoV-2) identified in Wuhan, China. Supporting these efforts, the CDC and the Chinese government have sequenced and submitted the coronavirus genome to the US NCBI GenBank® database (US Dept of Health and Human Services). With our worldwide manufacturing capabilities, IDT is uniquely able to provide robust qPCR primers and probes while avoiding contamination issues from synthesis of controls and related gene fragments.
The PrimeTime SARS-CoV-2/Flu Test includes a hot-start One-Step RT-qPCR Master Mix in addition to primers and probes designed according to the US Centers for Disease Control (CDC) qPCR detection assay. The 3-in-1 multiplex detection test for SARS-CoV-2, Flu A, and Flu B is currently being submitted by IDT for US FDA EUA approval.Be the first to know
IDT is honored to be the first company in the nation to have our primer and probe kits approved by the CDC for use as a key component of the CDC EUA testing protocol for the diagnosis and detection of COVID-19. We are proud to have rapidly achieved large-scale manufacturing of this key component which enables testing of millions of Americans for COVID-19.